trending Market Intelligence /marketintelligence/en/news-insights/trending/if6ioq5a7hn5bi0_wjqgyw2 content esgSubNav
In This List

Xencor prices common stock offering

Video

S&P Capital IQ Pro | Unrivaled Sector Coverage

Video

S&P Capital IQ Pro | Powering Your Edge

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Xencor prices common stock offering

Xencor Inc. priced an underwritten public offering of 7,300,000 common shares at $31 each.

The company expects to raise gross proceeds of about $226.3 million through the offering, which is expected to close on or about March 23, subject to customary closing conditions.

Xencor granted underwriters a 30-day overallotment option to buy up to an additional 1,095,000 shares.

The company plans to use net proceeds for working capital and general corporate purposes.

Leerink Partners and Piper Jaffray & Co. are acting as joint book-running managers for the offering, with Cantor Fitzgerald & Co., Wedbush PacGrow, Canaccord Genuity and BTIG as co-managers.

Monrovia, Calif.-based Xencor develops treatments for autoimmune diseases, asthma and allergic diseases and cancer.